|
EconStor >
Zentrum für Europäische Wirtschaftsforschung (ZEW), Mannheim >
ZEW Discussion Papers >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/10419/41440
|
| | |
Full metadata record
| DC Field | | Value | | Language |
| dc.contributor.author | | Kaiser, Ulrich | | en_US |
| dc.contributor.author | | Mendez, Susan J. | | en_US |
| dc.contributor.author | | Rønde, Thomas | | en_US |
| dc.date.accessioned | | 2010-11-04T10:49:12Z | | - |
| dc.date.available | | 2010-11-04T10:49:12Z | | - |
| dc.date.issued | | 2010 | | en_US |
| dc.identifier.uri | | http://hdl.handle.net/10419/41440 | | - |
| dc.description.abstract | | On April 1, 2005, Denmark changed the way references prices, a main determinant of reimbursements for pharmaceutical purchases, are calculated. The previous reference prices, which were based on average EU prices, were substituted to minimum domestic prices. Novel to the literature, we estimate the joint effects of this reform on prices and quantities. Prices decreased more than 26 percent due to the reform, which reduced patient and government expenditures by 3.0 percent and 5.6 percent, respectively, and producer revenues by 5.0 percent. The prices of expensive products decreased more than their cheaper counterparts, resulting in large differences in patient benefits from the reform. | | en_US |
| dc.language.iso | | eng | | en_US |
| dc.publisher | | Zentrum für Europäische Wirtschaftsforschung (ZEW) Mannheim | | en_US |
| dc.relation.ispartofseries | | ZEW Discussion Papers 10-062 | | en_US |
| dc.subject.jel | | I18 | | en_US |
| dc.subject.jel | | C23 | | en_US |
| dc.subject.ddc | | 330 | | en_US |
| dc.subject.keyword | | pharmaceutical markets | | en_US |
| dc.subject.keyword | | regulation | | en_US |
| dc.subject.keyword | | co-payments | | en_US |
| dc.subject.keyword | | reference pricing | | en_US |
| dc.subject.keyword | | asymmetric welfare effects | | en_US |
| dc.subject.stw | | Pharmazeutische Industrie | | en_US |
| dc.subject.stw | | Regulierung | | en_US |
| dc.subject.stw | | Pharmazeutisches Produkt | | en_US |
| dc.subject.stw | | Preis | | en_US |
| dc.subject.stw | | Wohlfahrtseffekt | | en_US |
| dc.subject.stw | | Dänemark | | en_US |
| dc.title | | Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark | | en_US |
| dc.type | | Working Paper | | en_US |
| dc.identifier.ppn | | 635644959 | | en_US |
| dc.rights | | http://www.econstor.eu/dspace/Nutzungsbedingungen | | en_US |
| dc.identifier.repec | | RePEc:zbw:zewdip:10062 | | - |
| Appears in Collections: | | Publikationen von Forscherinnen und Forschern des ZEW ZEW Discussion Papers
|
Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.
|